REPLIMUNE GROUP INC. - COMMON STOCK

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

07 Feb 2023 05:00:02 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jan 2023 05:05:00 By Nasdaq GlobeNewswire

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

04 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Replimune Announces Pricing of Public Offering

08 Dec 2022 18:04:34 By Nasdaq GlobeNewswire

Replimune Announces Proposed Public Offering

07 Dec 2022 13:04:04 By Nasdaq GlobeNewswire

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

07 Dec 2022 04:00:00 By Nasdaq GlobeNewswire

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

07 Dec 2022 03:30:00 By Nasdaq GlobeNewswire

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

23 Nov 2022 05:00:00 By Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on December 7, 2022

22 Nov 2022 05:00:01 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

03 Nov 2022 05:00:03 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

02 Nov 2022 13:01:00 By Nasdaq GlobeNewswire

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

07 Oct 2022 05:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

04 Aug 2022 05:00:02 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Aug 2022 13:01:00 By Nasdaq GlobeNewswire

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

03 Jun 2022 05:00:00 By Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Healthcare Conference

02 Jun 2022 05:00:01 By Nasdaq GlobeNewswire

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 May 2022 14:15:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

19 May 2022 05:00:01 By Nasdaq GlobeNewswire

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

30 Mar 2022 04:00:01 By Nasdaq GlobeNewswire